Diluted HEPS improved to 548.7cps (+11.3% y-y).
Turnover growth, +4.9% y-y to R9.1bn.
Group GPM decreased from 35.1% in FY22 to 34.9% in FY23.
Expense growth of +2.3%, with expenses to sales reducing to 22.5% compared to 23.0% LY.
OPM improved by 30bps to 12.4% (LY: 12.1%).
Dividend of 250cps (LY: 213cps).
Net cash fell to R81.9m from R345.5m LY.
Group saw organic volumes decline by 2.7% y-y due to lower demand for products used to treat COVID-19 and lower ARV tender sales. This was offset by the good demand in the OTC (revenue growth +10.8% y-y) and Prescription (revenue growth +2.0% y-y) portfolios.
On-boarded a range of ophthalmology products from Norvatis and E45 from Karo Pharma.
